Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nanobiosensors for Rheumatoid Arthritis Biomarkers: Advances and Clinical Translational Potential.

International journal of nanomedicine·2026
Same author

Sarcopenia as a prognostic factor in head and neck squamous cell carcinoma: a systematic review and meta-analysis.

European radiology·2026
Same author

Parallel anterior cingulate cortex pathways underlie dissociable social and attentional outputs.

Science advances·2026
Same author

Evolution-guided high yield production of potent Gα<sub>q/11</sub>-signalling inhibitors FR900359 and YM-254890.

Metabolic engineering·2026
Same author

High-precision freeform DLP bioprinting by thermo-reversible gelation.

Biomaterials·2026
Same author

Mechanisms and effects of ozone-pullulanase treatment on multiscale structures and in vitro digestibility of rice starch.

Food chemistry·2026

Related Experiment Video

Updated: Jun 12, 2026

Electrophoretic Delivery of &#x3B3;-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Complement system-mediated immunomodulation in epilepsy: From pathogenesis to therapeutic opportunities.

Linqian Peng1, Mengxuan Lu2, Mingyue Chen3

  • 1Collaborative Innovation Centre of Regenerative Medicine and Medical BioResource Development and Application Co-constructed by the Province and Ministry, Guangxi Key Laboratory of Regenerative Medicine, Center for Regenerative Medicine, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, 530021, PR China.

Neurochemistry International
|June 10, 2026
PubMed
Summary

The complement system, part of innate immunity, may drive epilepsy development and progression. Targeting this system offers potential for new disease-modifying epilepsy therapies.

Keywords:
Complement systemEpilepsyGlial cellImmunomodulationNeuroinflammation

More Related Videos

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

An Integrated Method for Crafting Flexible and Convenient Electrophysiological Optrodes for Multi-Region In Vivo Recording
06:55

An Integrated Method for Crafting Flexible and Convenient Electrophysiological Optrodes for Multi-Region In Vivo Recording

Published on: November 21, 2024

Related Experiment Videos

Last Updated: Jun 12, 2026

Electrophoretic Delivery of &#x3B3;-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

An Integrated Method for Crafting Flexible and Convenient Electrophysiological Optrodes for Multi-Region In Vivo Recording
06:55

An Integrated Method for Crafting Flexible and Convenient Electrophysiological Optrodes for Multi-Region In Vivo Recording

Published on: November 21, 2024

Area of Science:

  • Neuroscience
  • Immunology

Background:

  • Epilepsy is a neurological disorder with recurrent seizures, often resistant to current symptomatic treatments.
  • Existing antiseizure medications fail to halt disease progression or prevent epileptogenesis.
  • There is a critical need for novel disease-modifying therapies for epilepsy.

Purpose of the Study:

  • To review preclinical and clinical evidence linking complement system activation to epilepsy.
  • To explore complement-mediated mechanisms in neuroinflammation, synaptic remodeling, and glial proliferation in epilepsy.
  • To identify potential complement-based biomarkers and therapeutic targets for epilepsy.

Main Methods:

  • Systematic review of preclinical studies on complement activation in epilepsy models.
  • Analysis of clinical evidence regarding complement system involvement in human epilepsy.
  • Synthesis of data on neuroinflammation, synaptic plasticity, and glial responses.

Main Results:

  • Preclinical data strongly suggest abnormal complement activation contributes to epileptogenesis.
  • The complement system may act as a driver, not just a consequence, of neuroinflammation in epilepsy.
  • Evidence points to complement's role in synaptic remodeling and glial cell activity.

Conclusions:

  • Complement dysregulation is implicated as a pathogenic mechanism in epilepsy.
  • Targeting the complement system presents a promising avenue for developing disease-modifying epilepsy treatments.
  • Further clinical research is needed to validate complement-based strategies for epilepsy management.